S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES). Amendment 3 7.15.18
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Prevention
Scope
National
Locations
Cherry Creek Medical Center
Memorial Hospital Central
University of Colorado Hospital
Study ID
Protocol Number: 15-1590
More information available at ClinicalTrials.gov: NCT01349881
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers